Tempero Bio
Latest round
- Series B
Last raised
- Mar 2025
Total raised
- $70M
Investors
- 3
About Tempero Bio
Tempero Bio, Inc.Tempero Bio focuses on the advancement of treatments for substance use disorders. Founded in 2020 and headquartered in Oakland, US, the company has successfully completed 1 deal.Tempero Bio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for substance use disorders (SUDs) and related conditions. Their primary product offering, TMP-301, is an orally-available metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. This therapeutic candidate is being investigated for its efficacy in treating various SUDs, including Cocaine Use Disorder (CUD) and Alcohol Use Disorder (AUD), with ongoing research into its potential for addressing Opioid Use Disorder (OUD) and Polysubstance Use Disorder (PUD). TMP-301 operates by modulating glutamate signaling in the brain, which is crucial for normal brain function and is often disrupted in individuals suffering from addiction.S.While specific revenue figures for Tempero Bio are not disclosed, the company's revenue model centers on partnerships and collaborations primarily within the pharmaceutical and healthcare sectors. The firm focuses on advancing TMP-301 through clinical trials, and revenue may be generated through potential licensing agreements or joint ventures with larger pharmaceutical companies interested in commercializing their therapies. Transactions typically involve milestones associated with drug development phases, which could include payments upon successful completion of clinical trials or regulatory approvals.000 mn to advance TMP-301 through Phase 2 trials for alcohol and cocaine use disorders and support Phase 3 and preclinical studies for other indications. The company is focused on launching new products to further address the needs of individuals suffering from substance use disorders. Specific geographical expansion plans have not been detailed, but the emphasis remains on enhancing the clinical development of their therapies to reach critical milestones.
Who invested in Tempero Bio
3 investors across 1 round
See all investors in Tempero Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Mar 24, 2025
Amount
$70M
Investors
Questions about Tempero Bio
Who invested in Tempero Bio?
Tempero Bio has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Tempero Bio raised?
Tempero Bio has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Tempero Bio last raise money?
Tempero Bio's most recent round on record is a Series B, in Mar 2025.
What does Tempero Bio do?
Tempero Bio is a biotechnology company.
Where is Tempero Bio headquartered?
Tempero Bio is headquartered in Oakland, US.
Which VCs invest in companies like Tempero Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Tempero Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Tempero Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.